Please use this identifier to cite or link to this item:
Full metadata record
|dc.contributor.other||King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University||en_US|
|dc.contributor.other||Faculty of Medicine, Ramathibodi Hospital, Mahidol University||en_US|
|dc.contributor.other||Faculty of Medicine, Thammasat University||en_US|
|dc.contributor.other||Faculty of Medicine, Siriraj Hospital, Mahidol University||en_US|
|dc.contributor.other||Phramongkutklao College of Medicine||en_US|
|dc.contributor.other||Chiang Mai University||en_US|
|dc.identifier.citation||Journal of the European Academy of Dermatology and Venereology. Vol.32, No.6 (2018), 992-998||en_US|
|dc.description.abstract||© 2018 European Academy of Dermatology and Venereology Background: The lymphocyte transformation test (LTT) is a standard laboratory method to identify culprit drugs in patients with a history of drug-induced non-immediate hypersensitivity and is mainly performed during the recovery phase. The measurement of drug-specific interferon γ (IFN-γ)-releasing cells has been introduced to confirm culprit drugs, even during the acute phase of drug allergy. Objectives: This study aimed to evaluate the capability of the enzyme-linked immunospot assay (ELISpot) to detect drug-specific IFN-γ-releasing cells during the acute phase and the capability of LTT to identify culprit drugs during the recovery phase in patients presenting with severe cutaneous adverse reactions (SCARs). Methods: Peripheral blood mononuclear cells (PBMCs) from 23 SCAR patients were collected during the acute and recovery phases and assayed for drug-specific IFN-γ-releasing cells and lymphocyte proliferation, respectively. Results: Drug-specific IFN-γ-releasing cells were detectable in 73.9% of SCAR subjects (55.6% and 85.7% in patients who were and were not taking systemic steroids, respectively), whereas LTT results were positive in 52.2% of SCAR subjects. The frequencies of drug-specific IFN-γ-releasing cells were significantly higher in patients with positive LTT than in those with negative LTT (260.1 ± 110.0 and 46.6 ± 20.7 cells/106 PBMCs, P = 0.01). A significant correlation between the results of the IFN-γ ELISpot assay and LTT was demonstrated (r = 0.65, P value <0.01). Conclusion: The IFN-γ ELISpot assay could be a useful tool to identify culprit drugs in SCAR patients when culprit drug identification is urgently needed during the acute phase of drug allergy.||en_US|
|dc.title||The measurement of drug-induced interferon γ-releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions||en_US|
|Appears in Collections:||Scopus 2018|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.